British patients are testing the world’s first personalized mRNA cancer jab, potentially targeting melanoma, bladder, lung, and kidney cancers. This groundbreaking jab is customized for each individual, instructing the body to identify and halt cancer cells.
Follow us on:
Read More News #latestmalaysia
New skin cancer jab
A stage-two trial showed promising results in reducing cancer recurrence for melanoma patients, prompting the launch of a final trial. Led by University College London Hospitals NHS Foundation Trust, this innovative therapy, called individualized neoantigen therapy (INT), utilizes DNA sequencing and artificial intelligence to tailor treatment to each patient, offering hope for advancements in immunotherapy.
Table of Contents
